• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.

    4/3/25 8:30:00 AM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email

    DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will hold a conference call to review the company's first quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.

    To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the start time.

    About DexCom, Inc.

    Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently.

    Category: IR

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250403624532/en/

    DexCom, Inc.:

    Sean Christensen

    Vice President – Finance and Investor Relations

    [email protected]

    (858) 200-0200

    Get the next $DXCM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    6/16/2025$102.00Buy
    Truist
    5/30/2025$104.00Buy
    Goldman
    4/10/2025$85.00Outperform
    Mizuho
    2/3/2025$85.00 → $115.00Neutral → Buy
    Redburn Atlantic
    1/16/2025$86.00 → $104.00Neutral → Outperform
    Robert W. Baird
    7/26/2024$161.00 → $80.00Outperform → Neutral
    Robert W. Baird
    7/26/2024$145.00 → $75.00Overweight → Neutral
    JP Morgan
    5/30/2024$130.00Neutral
    Redburn Atlantic
    More analyst ratings

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dexcom Unveils New Report on Type 2 Diabetes Management in the U.S. at ADA 2025

      New State of Type 2 Report in the United States reports that a majority of healthcare professionals (HCPs) surveyed believe continuous glucose monitoring will have the potential to be more impactful on the future of Type 2 diabetes care than advancements in diabetes medications.1 Dexcom Warrior Lance Bass will share first-hand experience saying "Bye" to fingersticks* during panel at ADA. DexCom, Inc., the global leader in glucose biosensing, today released its "Dexcom State of Type 2 Report: Access and Attitudes Across the United States" ahead of the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The findings provide valuable insights into the percept

      6/18/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Announces Promotion of Jake Leach to the Expanded Role of President and COO

      DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose biosensing, today announced the promotion of Jake Leach to president, in addition to his current role as chief operating officer, which he has held since 2022. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250513806482/en/Dexcom's Jake Leach Promoted to Expanded Role of President and COO With more than 21 years of leadership experience at Dexcom, Mr. Leach helped steer the company's biosensing platforms since the launch of its first commercial system. In his chief operating officer role, he provides end-to-end responsibility for product development at

      5/13/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program

      DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 7% on a reported basis and 12% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $133.7 million or 12.9% of revenue, an increase of 190 basis points compared to the first quarter of 2024. Non-GAAP operating income* of $143.1 million or 13.8% of reported revenue, a decrease of 140 basis points compared to the first quarter of 2024. First Qu

      5/1/25 4:02:00 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    SEC Filings

    See more
    • SEC Form SD filed by DexCom Inc.

      SD - DEXCOM INC (0001093557) (Filer)

      5/29/25 4:35:26 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • DexCom Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - DEXCOM INC (0001093557) (Filer)

      5/13/25 8:31:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Amendment: DexCom Inc. filed SEC Form 8-K: Leadership Update

      8-K/A - DEXCOM INC (0001093557) (Filer)

      5/9/25 4:20:31 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care